Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Tumori ; 99(3): 408-15, 2013.
Article in English | MEDLINE | ID: mdl-24158071

ABSTRACT

AIMS AND BACKGROUND: Cancer registration in Sardinia covers 43% of the population and started in 1992 in the Sassari province. The aim of this paper is to provide estimates of the incidence, mortality and prevalence of seven major cancers for the entire region in the period 1970-2015. METHODS: The estimates were obtained by applying the MIAMOD method, a statistical back-calculation approach to derive incidence and prevalence figures starting from mortality and relative survival data. Estimates were compared with the available observed data. RESULTS: In 2012 the lowest incidence was estimated for stomach cancer and melanoma among men, with 140 and 74 new cases, respectively, per 100,000. The mortality rates were highest for lung cancer and were very close to the incidence rates (77 and 95 per 100,000, respectively). In women, breast was by far the most frequent cancer site both in terms of incidence (1,512 new cases) and mortality (295 deaths), followed by colon-rectum (493 cases and 201 deaths), lung (205 cases and 167 deaths), melanoma (106 cases and 15 deaths), stomach (82 cases and 61 deaths), and uterine cervix (36 cases and 19 deaths). The highest prevalence was estimated for breast cancer (15,180 cases), followed by colorectal cancer with about 7,300 prevalent cases in both sexes. CONCLUSION: This paper provides a description of the burden of the major cancers in Sardinia until 2015. The comparisons between the estimated age-standardized incidence rates and those observed in the Sassari registry indicate good agreement. The estimates show a general decrease in cancer mortality, with the exception of female lung cancer. By contrast, the prevalence is steeply increasing for all considered cancers (with the only exception of cancer of the uterine cervix). This points to the need for more strongly supporting evidence-based prevention campaigns focused on contrasting female smoking, unhealthy nutrition and sun exposure.


Subject(s)
Neoplasms/epidemiology , Adult , Aged , Aged, 80 and over , Breast Neoplasms/epidemiology , Colorectal Neoplasms/epidemiology , Cost of Illness , Female , Humans , Incidence , Italy/epidemiology , Lung Neoplasms/epidemiology , Male , Melanoma/epidemiology , Middle Aged , Neoplasms/mortality , Prevalence , Prostatic Neoplasms/epidemiology , Registries , Sex Distribution , Skin Neoplasms/epidemiology , Stomach Neoplasms/epidemiology , Survival Rate/trends , Uterine Cervical Neoplasms/epidemiology
2.
BMC Cancer ; 9: 62, 2009 Feb 20.
Article in English | MEDLINE | ID: mdl-19232099

ABSTRACT

BACKGROUND: Germline mutations in BRCA1 or BRCA2 genes have been demonstrated to increase the risk of developing breast cancer. Conversely, the impact of BRCA mutations on prognosis and survival of breast cancer patients is still debated. In this study, we investigated the role of such mutations on breast cancer-specific survival among patients from North Sardinia. METHODS: Among incident cases during the period 1997-2002, a total of 512 breast cancer patients gave their consent to undergo BRCA mutation screening by DHPLC analysis and automated DNA sequencing. The Hakulinen, Kaplan-Meier, and Cox regression methods were used for both relative survival assessment and statistical analysis. RESULTS: In our series, patients carrying a germline mutation in coding regions and splice boundaries of BRCA1 and BRCA2 genes were 48/512 (9%). Effect on overall survival was evaluated taking into consideration BRCA2 carriers, who represented the vast majority (44/48; 92%) of mutation-positive patients. A lower breast cancer-specific overall survival rate was observed in BRCA2 mutation carriers after the first two years from diagnosis. However, survival rates were similar in both groups after five years from diagnosis. No significant difference was found for age of onset, disease stage, and primary tumour histopathology between the two subsets. CONCLUSION: In Sardinian breast cancer population, BRCA2 was the most affected gene and the effects of BRCA2 germline mutations on patients' survival were demonstrated to vary within the first two years from diagnosis. After a longer follow-up observation, breast cancer-specific rates of death were instead similar for BRCA2 mutation carriers and non-carriers.


Subject(s)
Breast Neoplasms/genetics , Breast Neoplasms/mortality , Genes, BRCA2 , Germ-Line Mutation , Adult , Aged , Aged, 80 and over , Breast Neoplasms/pathology , DNA Mutational Analysis , Female , Genes, BRCA1 , Humans , Italy/epidemiology , Middle Aged , Neoplasm Staging , Survival Rate , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...